Ketamine clinics have increasingly garnered investor interest. At-home provider Mindbloom, for example, has raised roughly $45 million in venture capital. As an anesthetic in surgical operations, ketamine is already FDA-approved and is also lawfully prescribed off-label. Accordingly, today a healthcare clinic can treat its patients without waiting on the regulatory path that still restricts other psychedelic compounds. Relatively speaking, this has given the ketamine industry a head start of sorts but does not inherently determine whether an investment in the ketamine space actually holds value. Part of this depends on whether a practice was built on a regulatorily compliant foundation or can easily be unwound by a regulator.
At their core, ketamine clinics are businesses sitting at a nexus where multiple bodies of law overlap. Specifically, healthcare licensing, controlled substance rules, telehealth regulation, and employment classification all apply at once. A flaw with regard to any single one of these can directly impact valuation. Investors evaluating clinics should thus avoid treating them as ordinary small businesses and avoid costly mistakes that become apparent only after closing. Delic Holdings bought Ketamine Wellness Centers, then billed as the largest ketamine clinic chain in the country, for $10 million in 2021. After all thirteen of its clinics closed in March 2023, Delic agreed to sell the business for $1.15 million plus assumed debt. Additionally, Toronto-based Field Trip Health burned through nearly CA$100 million in investor money before selling its U.S. clinics for about $750,000.
First, the Ownership Structure
Most states follow some version of the corporate practice of medicine doctrine, which limits who may own a medical practice and share in its professional fees. Many ketamine ventures thus rely upon a management services organization (MSO) that controls non-clinical operations while a licensed physician owns and operates the clinical entity. This model has been around for many years but must follow each state’s unique rules. Among these rules is that management fees should reflect fair market value for the services provided, as multiple states require. A management agreement that provides for fee-splitting invites regulatory scrutiny that the structure was designed to avoid. Accordingly, prudent investors must review the physician-owner’s stock transfer restrictions and succession provisions, considering that the clinical entity depends on a licensed owner who can remain in place for many years or alternatively may be replaced without impinging upon patient care.
Controlled Substances and Telehealth
Ketamine is a Schedule III controlled substance that requires DEA registration and state controlled substance registrations. If a clinic prescribes remotely, federal telehealth prescribing rules for controlled substances also apply. For example, the Ryan Haight Act generally requires at least one in-person medical evaluation before a practitioner may prescribe a controlled substance via the internet. While pandemic-era exceptions to this rule have been extended many times, the current extension runs through December 31, 2026. A remote care model that depends on a temporary flexibility carries a diligence-related risk that should be addressed in the deal terms. Diligence should also confirm that each clinical location maintains its own registration and that inventory logs reconcile with dispensing records. This is because a discrepancy found during a DEA inspection can lead to suspension or revocation of the registration.
Informed Consent
Off-label prescribing and usage increase the need for informed consent. Because ketamine is not FDA-approved for any psychiatric disorder, consent forms should explain that it is being used outside its approved indication and should describe the route of administration the clinic actually uses, including sublingual or at-home ketamine formulations. Clinics treating patients by video must also abide by any state-specific telehealth consent rules. Weak consent documentation tends to become apparent later in malpractice claims and licensing board complaints, making it hard to cure after the fact. At-home models also raise screening questions: a 2025 wrongful death lawsuit against Mindbloom alleges that the company onboarded a patient whose medical history should have ruled out unsupervised at-home ketamine therapy.
Staffing, Supervision, and Worker Classification
States differ widely as to how nurse practitioners and physician assistants may practice, including collaboration requirements and limits on the number of clinicians one physician may oversee. Such limits thus determine the scalability of this model across multiple locations. Classification of clinicians as independent contractors may work well for an operating plan, but worker misclassification in addition to fee-splitting and anti-kickback concerns tied to provider compensation (e.g., state anti-kickback and patient brokering laws, some of which still apply even to cash-pay services), may turn an otherwise ordinary staffing choice into a legal liability that follows and haunts the buyer.
Revenue Quality and Marketing
Many ketamine clinics choose to follow the cash pay model because insurance coverage for off-label ketamine treatment remains limited. By contrast, Johnson & Johnson’s FDA-approved esketamine nasal spray, Spravato, passed $1 billion in sales in 2024 and grew another 57% in 2025. Diligence must evaluate the durability of a clinic’s payer mix and whether membership or package pricing remains compliant with state consumer protection laws. Advertising deserves the same review because efficacy-related claims for depression or PTSD attract attention from both regulators and plaintiffs.
Separation from Other Psychedelics
Some ketamine clinic operators pitch psilocybin or MDMA as the next growth stage in this broad therapeutic space. However, both alternatives remain Schedule I under federal law. Moreover, while state-specific psilocybin programs, especially those in Oregon and Colorado, exist, they also operate under their own licensing frameworks. Thus, a ketamine business that is lawful in its own right must be evaluated on its own, apart from any business line that depends on regulatory change that has not yet been effectuated, if ever.
Reaching into the Clinical Record
Prudent investors may reap numerous financial benefits in this developing space. “Prudent” here entails healthcare due diligence covering licenses, clinical protocols, adverse event history, malpractice coverage, and any regulatory inquiry, alongside the financials, with representations and warranties and indemnities that properly place risk where necessary. Consulting with healthcare regulatory counsel before the term sheet is signed usually costs far less than being forced to fix a structure after closing. As a practical matter, investors should make early requests for the clinic’s history of board complaints and any DEA inspection reports. In a way, these documents often say more about the business than even its own financial statements do.
Disclaimer: This industry insight is for general information only, is not legal advice, and does not create an attorney-client relationship.